The Science · La Ciencia

The evidence behind the protocols.

Three landmark trials. 5,303 randomized patients. Every clinical claim REMEVi makes traces back to a peer-reviewed source — and every source is linked below, so you can read it yourself.

The Evidence · La Evidencia

Read the trials. Not the press release.

Two compounds. Three landmark trials. 5,303 randomized patients. The data is public, peer-reviewed, and is the same studies that supported FDA approval of Wegovy and Zepbound. Read it for yourself.

n = 5,303 RANDOMIZED · 3 TRIALS

NEJM 2021 · 384:989–1002

STEP-1

Once-Weekly Semaglutide in Adults with Overweight or Obesity

Wilding JPH, Batterham RL, Calanna S, et al.

−14.9% body weight at 68 weeks vs −2.4% placebo (n=1,961)

DOI 10.1056/NEJMoa2032183 READ →

NEJM 2022 · 387:205–216

SURMOUNT-1

Tirzepatide Once Weekly for the Treatment of Obesity

Jastreboff AM, Aronne LJ, Ahmad NN, et al.

−20.9% body weight at 72 weeks at 15 mg dose (n=2,539)

DOI 10.1056/NEJMoa2206038 READ →

JAMA 2021 · 325:1414–1425

STEP-4

Effect of Continued Weekly Semaglutide vs Placebo on Weight Maintenance

Rubino D, Abrahamsson N, Davies M, et al.

Continued therapy maintained loss; withdrawal regained 6.9% (n=803)

DOI 10.1001/jama.2021.3224 READ →

· FIG. 00 · The Molecule · La Molécula ·

This is what does the work.

GLP-1 (7–37) · α-HELIX
31 RESIDUES · 3.6 / TURN
DRAG TO ROTATE · CLICK A RESIDUE

FIG. 00 · SEMAGLUTIDE
C₁₈₇H₂₉₁N₄₅O₅₉

HYDROPHOBIC
POLAR
POSITIVE
NEGATIVE
MODIFIED

· SPEC SHEET ·NEJM 2021 · STEP-1

Semaglutide

Long-acting analog · 30 aa

Molecular formulaC₁₈₇H₂₉₁N₄₅O₅₉

Molecular weight4,113 Da

Half-life168 hrs (7 days)

Dose cadenceOnce-weekly

Receptor(s)GLP-1R

· RESIDUE · ANNOTATION ·

Lys²⁶ · the semaglutide site

Semaglutide attaches a C18 fatty diacid + γGlu + 2×OEG linker here. The fatty chain reversibly binds serum albumin — your bloodstream becomes a slow-release reservoir. Once-weekly dosing exists because of this single residue.

· WHERE IT ACTS · DÓNDE ACTÚA ·4 RECEPTOR SITES · ONE MOLECULE

Hypothalamus

−68%

food cravings

Reduces "food noise" & reward-driven eating

Stomach

−30%

caloric intake

Slows gastric emptying, extends satiety

Pancreas

−1.5%

avg. HbA1c

Glucose-dependent insulin · suppresses glucagon

Adipose

89%

lean mass kept

Lipolysis · preserves lean muscle mass

Convinced by the data?

A licensed provider reviews your health history and tells you if a GLP-1 protocol is right for you. Free, no card required.

See if you qualify